59 results about "Portal hypertension" patented technology

Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

The devices and methods generally relate to vibratable sensors for measuring ambient fluid pressure, in particular implantable sensors. The devices and methods are particularly well-suited to implantation within the body of a living animal or human to monitor physiological conditions, such as portal and/or hepatic venous blood pressure, and allow frequent, remote interrogation of venous pressure using the resonance frequency of an implanted sensor. The sensor devices are relatively small compared to conventional devices for measuring fluid pressure and can be implanted in the porto-hepatic venous system, whereas conventional devices are too large. The small size of the device is accomplished by using a thick sensor membrane, compared to conventional devices, and by limiting the size of additional elements of the device relative to the size of the sensor membrane. The thicker sensor member also obviates the need for multiple sensor arrays and maintains the accuracy and robustness of the sensor device. A data capture, processing, and display system provides a pressure measurement reading, and is particularly well-suited for detecting portal hypertension in patients with liver disorders.

The present invention provides methods for treating or preventing portal hypertension comprising administering to a patient in need of such treatment or prevention at least one Rev-erb modulating agent (REMA) in an amount effective to treat or prevent said portal hypertension. The REMA can be SR6452 or a related compound, such as SR9009 or SR9011. The amount of the REMA administered can comprises a quantity sufficient to modulate Rev-erbα expression, activity, and/or subcellular location and/or to inhibit or reverse hepatic stellate cell (HSC) activation and contractility.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

The invention describes novel diuretic compounds comprising at least one heterocyclic nitric oxide donor group, or pharmaceutically acceptable salts thereof, and novel composition comprising at least one diuretic compound comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention comprising at least one heterocyclic nitric oxide donor group, and optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidatives stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; and (p) treating sexual dysfunctions. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

An agent for preventing or treating portal hypertension comprising a compound represented by the general formula (I): wherein R<1 >represents a group capable of forming an anion, etc.; X represents a bond or a spacer; n is an integer of 1 or 2; ring A is benzene ring which may be further substituted; R<2 >represents a group capable of forming an anion, etc.; and R<3 >represents a hydrocarbon group which may bonded via a hetero atom, and may be substituted, a salt thereof or a prodrug thereof, is provided. This agent has sufficiently excellent properties as medicine, since it has excellent prophylactic and therapeutic effects on portal hypertension without any side effect, etc.

The invention discloses a solid beverage capable of assisting to lower hypertension, hyperglycemia and hyperlipidemia and belongs to the technical field of health-care foods. The solid beverage is prepared from the following components in parts by weight by mixing: 1 to 10 parts of chitosan oligosaccharide, 5 to 25 parts of oat-beta-glucan, 5 to 10 parts of xylo-oligosaccharide, 40 to 80 parts of fructooligsacchride and 5 to 20 parts of inulin. The solid beverage capable of assisting to lower the hypertension, the hyperglycemia and the hyperlipidemia, disclosed by the invention, can be used for preventing or treating a lot of diseases, such as the hypertension, the hyperglycemia and the hyperlipidemia; the solid beverage has the effects of promoting digestion, losing weight, delaying ageing, lowering the cholesterol and improving the immunity, can be used for inhibiting a plurality of types of diseases including arteriosclerosis and the like and has no toxic or side effect; the effective rate of lowering the hypertension, the hyperglycemia and the hyperlipidemia reaches 98 percent or more.

The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines.

The invention provides a construction method of a radiology-based hepatic venous pressure gradient (rHVPG) calculation model. An advantageous hepatic vein pressure gradient calculation model can be constructed on this basis, and a new approach is provided to calculate the early noninvasive indexes of patients with portal hypertension. The invention also provides a rHVPG calculation system. The method can overcome many limitations of an existing noninvasive measurement method. The rHVPG calculation system is feasible, and is expected to provide a new idea for the noninvasive measurement of portal pressure, and plays an active role in improving the quality of life of patients with portal hypertension and reducing the burden of disease in families and society.

The invention relates to a medicament for treating cirrhosis and portal hypertension, which is characterized by being prepared from panax ginseng, szechwon tangshen root, astragalus, amomum fruit, large-headed atractylodes rhizome, Indian buead, Chinese angelica, rehmanniae vaporata, tuber fleeceflower root, suberect spatholobus stem, white paeony root and the like. Compared with medicaments for promoting blood circulation, removing blood stasis and softening the liver merely, the medicament for treating the cirrhosis and the portal hypertension has better effect of tonifying qi and invigorating blood circulation; and compared with medicaments for promoting blood circulation and softening hard lumps merely, the medicament for treating the cirrhosis and the portal hypertension has excellent effect of soothing liver and relaxing vein on the relieving of the portal hypertension.

The inventors have discovered that food and pharmaceutical compositions containing (−)-hydroxycitric acid, its salts, amides and esters can be employed for delaying gastric emptying and increasing receptive relaxation for preventing and treating diverse conditions. The invention provides for HCA-containing compound useful to delay gastric emptying and increase receptive relaxation for preventing and treating diverse conditions, e.g., stomach ulcers, portal hypertension, liver dysfunction, diabetes and obesity. The invention provides methods for delaying gastric emptying and increasing receptive relaxation in individuals. The invention also provides methods of preventing or treating disorders or conditions related to aberrant gastric emptying and receptive relaxation.

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors.

A method of inducing liver regeneration in a damaged liver tissue region of an individual is provided. The method including the step of providing at least two distinct growth factors to the damaged liver tissue region of the individual, at least one of the at least two distinct growth factors being an angiogenic factor.

The present invention is directed to methods of treating and/or ameliorating portal hypertension by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof.

The invention discloses a medicinal composition for treating primary hypertension, and relates to the technical field of Chinese medicines. The medicinal composition is prepared from the following active ingredients in part by weight: 10 to 15 parts of chrysanthemum, 10 to 15 parts of mulberry leaf, 12 to 16 parts of lumbricus, 12 to 16 parts of baical skullcap root, 12 to 16 parts of figwort root, 18 to 22 parts of root of red-rooted salvia, 12 to 16 parts of rehmannia root, 10 to 15 parts of white paeony root, 8 to 12 parts of dwarf lilyturf tuber, 18 to 22 parts of root of doubleteeth pubescent angelica and 12 to 16 parts of Japanese thistle herb. The medicinal composition can effectively relieve primary hypertension and generally does not have side effect; and the hypotensive effect is remarkable, mild and lasting.

The invention discloses a medicine composition for treating primary hypertension and a preparation method thereof. The medicine composition is mainly prepared from vitis flexuosa thumb., pternopetalum nudicaule(de Boiss.) hand.-mazz, botrychium japonicum, a rubus pluribracteatus root, thysanolaena maxima, brassica integrifolia, a paper mulberry root, an artocarpus hypargyreus root, oberonia iridifolia Lindl, piptanthus concolor craib, henon bamboo juvenile leaves, phyllanthus emblica, evening primrose extract, lemon extract and moyeam tea extract. Based on the traditional Chinese medicine theory, the Medicine composition is applied according to symptoms, the formula is precise, reasonable compatibility is achieved, and the Medicine composition has the functions of removing heat to cool blood, encouraging production of body fluid to extinguish thirst, removing toxicity for detumescence, removing liver-fire for improving eyesight, stopping bleeding and reducing blood pressure, can further effectively remove toxicity and relieve mental stress, promotes a normal organism diet, clears away smoke and dispels the effects of alcohol, and is remarkable in treatment effect, mild in medicinal effect and free of side effects. The preparation technology of the Medicine composition for treating primary hypertension is simple, the production cost is low, and good medical value is achieved.

The invention relates to a magnetic device used for cardia-esophagogastric varices sugiura. The device comprises two permanent magnet conduit groups of the same structure and with inverse magnetic poles, wherein permanent magnets are positioned in the pipe cavities of the conduits; a non magnetic plastic sheet is arranged between every two magnets; two permanent magnet conduit groups with the corresponding size and shape are adopted to block the cardia-esophagogastric varices in a squeezing mode, so as to avoid the defects of large trauma and multiple complications of laparotomy; side holes on conduit walls can drain enterocoelia exudate, reduce the abdominal pressure and prompt the function recovering of an enterocoelia visceral organ; and in addition, the vein blocking-up can be carried out repeatedly by stages, thus portal hypertension stomach illness caused by excessive sugiura can be avoided, and the part of the conduit remained in vitro can be directly pulled out, thus the foreign matter can not be reminded in vivo.

The invention relates to a medicinal hat for assisting in treating primary hypertension. The following dry powdery Chinese medicaments are filled in the medicinal hat: 20 to 35 grams of kudzuvine root, 18 to 20 grams of pearl layer powder, 15 to 20 grams of belvedere fruit, 15 to 18 grams of magnet powder, 16 to 20 grams of sea-ear shell, 18 to 25 grams of white peony root, 15 to 18 grams of tall gastrodia tuber, 13 to 15 grams of gambir plant, 12 to 15 grams of achyranthes root, 10 to 15 grams of chrysanthemum, 10 to 16 grams of pubescent angelica root, 8 to 15 grams of safflower and 8 to 18 grams of corn stigma. The medicinal hat has good effect of assisting in treating the primary hypertension.

The invention relates to application of protein C in treating hepatic portal hypertension, relates to the relevant research of the protein C and portal hypertension, and also relates to protein C inhibitors including miRNA. The protein C inhibitor (miRNA) can inhibit the proliferation of hepatocytes and promote the apoptosis of the hepatocytes, which can reduce hyperplasia tissue of hepatic sinusoids to make portal venous flow smooth and reduce the portal pressure, thereby opening up new research prospects for the treatment of the portal hypertension (especially portal vein cavernous transformation) and providing new ideas for the deep development of miRNA drugs and clinical treatment.

The invention provides instant porridge for recovering intestinal flora balance of patients suffering from primary hypertension and a making method of the instant porridge. The instant porridge is prepared from the following raw materials in parts by weight: 5-10 parts of lentinus edodes, 5-10 parts of semen cassia, 5-10 parts of apium graveolens, 5-10 parts of poria cocos, 2.5-5 parts of lucid ganoderma, 2.5-5 parts of dandelion, 2.5-5 parts of ramalina, 2.5-5 parts of hericium erinaceus, 2.5-5 parts of cordyceps militaris, 2.4-6 parts of agaricus blazei murill, 35-50 parts of shii-take crude fibers, 35-50 parts of wheat bran and 75-100 parts of corn. By adopting the instant porridge, the health situations of patients can be effectively improved by regulating intestinal flora distribution of patients suffering from primary hypertension, meanwhile, for common people, the instant porridge has a relatively good effect of preventing primary hypertension when being taken for a long time. The instant porridge is simple in step, convenient to operate and good in practicability.